ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Moderna, known for its messenger RNA (mRNA) vaccines for COVID-19, is branching out into gene editing. Moderna has struck a research collaboration with Metagenomi, a start-up focused on discovering new enzymes for CRISPR gene editing and other gene-editing systems. The companies will encode the systems in mRNA molecules and package the molecules in Moderna’s lipid nanoparticles to treat genetic diseases. Metagenomi will get an undisclosed payment and investment from Moderna.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter